Century Therapeutics Inc (IPSC) Stock Price, Quote & News

Company Profile

Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 817 5790

Website: www.centurytx.com

Address:

25 North 38th Street, 11th Floor, Philadelphia, United States

ka1954 Jun. 27 at 11:22 PM

$ACRV $GBIO $IPSC $XFOR why am i seeing so many stocks dumping right before close? GBIO, ACRV, IPSC

1 · Reply

biochirp Jun. 25 at 2:47 PM

$IPSC shut down and return cash to shareholders NOW!!

0 · Reply

RedTex_ Jun. 24 at 4:57 PM

$MULN $YYAI $HBIO $IPSC This guy is a pump and dump fiend. Please report him for cross posting naked lies. He does this every day. 👇$NMRA $DVLT

1 · Reply

Profitier Jun. 24 at 2:48 PM

$IPSC Still adding..

0 · Reply

Profitier Jun. 20 at 4:00 PM

$IPSC Numerous employees just got stock options to buy @.6, that typically means the company is expecting the stock price to be well above that giving their employees the benefit of buying cheaper.. Huge current insider ownership as well$$ https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001850119&type=&dateb=&owner=include&count=40&search_text=

0 · Reply

Ned_Nosurname Jun. 17 at 12:19 AM

$IPSC The posters https://www.centurytx.com/wp-content/uploads/EULAR-2025-alpha-beta-CAR-T-cells.pdf https://www.centurytx.com/wp-content/uploads/EULAR-2025-CNTY-101.pdf

0 · Reply

Sn1perWolf Jun. 16 at 10:50 AM

$IPSC

0 · Reply

Profitier Jun. 11 at 9:31 PM

$IPSC Good stuff - https://x.com/biomedicalrx/status/1932895251376844853?s=46

0 · Reply

Profitier Jun. 11 at 8:35 PM

$IPSC took a new position @.583 today$$$$$

0 · Reply

Peterson28 Jun. 7 at 5:38 AM

$IPSC Came across this from FATE’s board. Wondering what happened here. Trading at 0.2x cash?

1 · Reply

Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress

May 15, 2025, 4:01 PM EDT - 6 weeks ago

Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 28, 2025, 4:30 PM EDT - 2 months ago

Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

Mar 19, 2025, 4:01 PM EDT - 3 months ago

Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Nov 26, 2024, 7:00 AM EST - 7 months ago

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 5, 2024, 9:05 AM EST - 8 months ago

Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 4, 2024, 7:00 AM EST - 8 months ago

Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Sep 26, 2024, 7:00 AM EDT - 9 months ago

Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer

Aug 8, 2024, 7:30 AM EDT - 11 months ago

Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jun 20, 2024, 11:07 AM EDT - 1 year ago

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting

May 9, 2024, 7:30 AM EDT - 1 year ago

Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 19, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 14, 2024, 7:30 AM EDT - 1 year ago

Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

Mar 5, 2024, 6:03 PM EST - 1 year ago

Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Feb 1, 2024, 7:00 AM EST - 1 year ago

Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Dec 9, 2023, 12:00 PM EST - 1 year ago

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

Dec 6, 2023, 7:30 AM EST - 1 year ago

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

$Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus$

Dec 6, 2023, 7:30 AM EST - 1 year ago

Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

Nov 21, 2023, 7:00 AM EST - 1 year ago

Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 9, 2023, 7:01 AM EST - 1 year ago

Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 7:00 AM EST - 1 year ago

Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases

Sep 26, 2023, 7:00 AM EDT - 1 year ago

Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference

Aug 9, 2023, 7:30 AM EDT - 2 years ago

Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

May 11, 2023, 7:30 AM EDT - 2 years ago

Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

Apr 17, 2023, 7:00 AM EDT - 2 years ago

Century Therapeutics to Present at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit

Apr 12, 2023, 8:30 AM EDT - 2 years ago

Century Therapeutics Announces Leadership Changes

Mar 16, 2023, 7:30 AM EDT - 2 years ago

Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates

Mar 15, 2023, 4:01 PM EDT - 2 years ago

Century Therapeutics to Present at the AACR Annual Meeting 2023

Feb 21, 2023, 7:00 AM EST - 2 years ago

Century Therapeutics to Present at Upcoming Investor Conferences

$Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas$

Feb 8, 2023, 7:30 AM EST - 2 years ago

Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas

Jan 19, 2023, 8:58 AM EST - 2 years ago

5 Health Care Stocks That Are Diving - And May Rally

FATE SNPX TECH

Jan 10, 2023, 7:33 AM EST - 2 years ago

Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)

FATE THRD VERA

Jan 9, 2023, 9:06 PM EST - 2 years ago

Century Therapeutics closes its Seattle hub amid wider cuts, departure of R&D head

Jan 5, 2023, 4:01 PM EST - 2 years ago

Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026

Jan 4, 2023, 7:00 AM EST - 2 years ago

Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 22, 2022, 7:00 AM EST - 2 years ago

Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

Nov 11, 2022, 7:00 AM EST - 2 years ago

Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates

Nov 10, 2022, 7:30 AM EST - 2 years ago

Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

Nov 2, 2022, 7:05 AM EDT - 2 years ago

Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022

Oct 5, 2022, 4:05 PM EDT - 2 years ago

Century Therapeutics to Present at the SITC 37th Annual Meeting

Oct 3, 2022, 7:00 AM EDT - 2 years ago

Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors

Sep 26, 2022, 7:00 AM EDT - 2 years ago

Century Therapeutics to Present at Chardan's 6th Annual Genetic Medicines Conference

Sep 6, 2022, 7:00 AM EDT - 3 years ago

Century Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 25, 2022, 7:30 AM EDT - 3 years ago

Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection

Aug 11, 2022, 7:30 AM EDT - 3 years ago

Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

Jun 24, 2022, 4:30 PM EDT - 3 years ago

Century Therapeutics Announces Its Addition to the Russell Microcap® Index

ka1954 Jun. 27 at 11:22 PM

$ACRV $GBIO $IPSC $XFOR why am i seeing so many stocks dumping right before close? GBIO, ACRV, IPSC

1 · Reply

biochirp Jun. 25 at 2:47 PM

$IPSC shut down and return cash to shareholders NOW!!

0 · Reply

RedTex_ Jun. 24 at 4:57 PM

$MULN $YYAI $HBIO $IPSC This guy is a pump and dump fiend. Please report him for cross posting naked lies. He does this every day. 👇$NMRA $DVLT

1 · Reply

Profitier Jun. 24 at 2:48 PM

$IPSC Still adding..

0 · Reply

Profitier Jun. 20 at 4:00 PM

0 · Reply

Ned_Nosurname Jun. 17 at 12:19 AM

$IPSC The posters https://www.centurytx.com/wp-content/uploads/EULAR-2025-alpha-beta-CAR-T-cells.pdf https://www.centurytx.com/wp-content/uploads/EULAR-2025-CNTY-101.pdf

0 · Reply

Sn1perWolf Jun. 16 at 10:50 AM

$IPSC

0 · Reply

Profitier Jun. 11 at 9:31 PM

$IPSC Good stuff - https://x.com/biomedicalrx/status/1932895251376844853?s=46

0 · Reply

Profitier Jun. 11 at 8:35 PM

$IPSC took a new position @.583 today$$$$$

0 · Reply

Peterson28 Jun. 7 at 5:38 AM

$IPSC Came across this from FATE’s board. Wondering what happened here. Trading at 0.2x cash?

1 · Reply

BOS7 Jun. 6 at 6:22 PM

$IPSC chart looks good. Strong Q1 earning. Long swing idea

0 · Reply

future__investor Jun. 6 at 3:34 PM

$IPSC

0 · Reply

Moserale Jun. 6 at 2:08 PM

$IPSC pop day??!

1 · Reply

stonkuru Jun. 4 at 6:38 PM

$IPSC

0 · Reply

stonkuru Jun. 4 at 6:24 PM

$IPSC

0 · Reply

stonkuru Jun. 4 at 6:07 PM

$IPSC $MULN $CRWV $APLD

0 · Reply

stonkuru Jun. 4 at 6:06 PM

$IPSC buys coming in

0 · Reply

stonkuru Jun. 4 at 6:02 PM

$IPSC

0 · Reply

stonkuru Jun. 4 at 5:50 PM

$IPSC https://www.zacks.com/stock/news/2472608/century-therapeutics-inc-ipsc-q1-earnings-and-revenues-top-estimates?cid=CS-STOCKTWITS-HL-tale_of_the_tape%7Cyseop_template_4-2472608&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_513_2472608

0 · Reply

stonkuru Jun. 4 at 5:49 PM

$IPSC $MULN roll over

0 · Reply

stonkuru Jun. 4 at 5:41 PM

$IPSC completely undervalued based on recent earnings. Hoping for a rocket after their presentations

0 · Reply

stonkuru Jun. 4 at 5:36 PM

$IPSC $CRWV

0 · Reply

Market Cap	48.90M
Revenue (ttm)	6.59M
Net Income (ttm)	-126.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,920.64%
Debt to Equity Ratio	0.00

Volume	6,185,600
Avg Vol	922,890
Day's Range	N/A - N/A
Shares Out	86.16M
Stochastic %K	0%
Beta	1.77
Analysts	Strong Sell
Price Target	$4.40